期刊文献+

盐酸吡贝地尔口崩片的处方筛选 被引量:6

Formula Optimization of Piribedil Hydrochloride Oral-Disintegrating Tablets
原文传递
导出
摘要 目的:采用正交试验筛选盐酸吡贝地尔口崩片处方并进行相关指标考察。方法:以崩解剂交联聚乙烯吡咯烷酮(PVPXL)、填充剂预胶化淀粉和助流剂微粉硅胶的用量为考察因素,以口崩片的崩解时间、润湿时间和混悬稳定性等为评价指标进行正交试验,确定最佳处方,绘制最优处方制剂的溶出曲线。结果:筛选的盐酸吡贝地尔口崩片最佳处方为PVPXL、预胶化淀粉、微粉硅胶用量分别为15%、20%、15%,所制制剂约在30s内崩解完全,药物在2min内基本溶出。结论:经筛选的制备工艺所制制剂符合《中国药典》相关要求。 OBJECTIVE: To optimize the formula of piribedil hydrochloride orally disintegrating tablets and to investigate their related indexes. METHODS: Taking the contents of crospovidone (PVP XL) (disintegrating agent), amylum pregela tinisatum (loading agent) and Gum Acacia (glidant) as factors, the disintegrating time(td), the wet time (t) and the suspend stability(△A) as the evaluate indexes to carry on the orthogonal experimental to optimize the formula. The dissolution curve of the optimized formula was drawn. RESULTS: The optimized formula for the piribedil hydrochloride orally disintegrating tablets were as follows: the contents of crospovidone (PVP XL), amylum pregelatinisatum and Gum Acacia were 15%, 20%, and 15% respectively. The prepared orally disintegrating tablets disintegrated completely within 30s and dissolved basically within 2min. CONCLUSION: The prepared preparation can meet the related standards specified of China Pharmacopeia.
出处 《中国药房》 CAS CSCD 北大核心 2008年第22期1727-1729,共3页 China Pharmacy
关键词 盐酸吡贝地尔 口崩片 制备工艺 溶出度 稳定性 Donepezil hydrochloride Orally disintegrating tablets Preparation process Dissolution Stability
  • 相关文献

参考文献4

二级参考文献18

  • 1Corrodi H, Fuxe K, Ungersted U. Evidence for a new type of dopamine receptor stimulating agent[J]. J Pharm Pharmacol, 1971,23: 989 - 991.
  • 2Smith LA, Jackson MG, Bonhomme C, et al. Transdermal administration of piribedil reverses MPTP - induced motor deficits in the common marmoset [J ]. Clin Neuropharm, 2000,23:133 - 142.
  • 3Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson's disease: A multicenter study [J]. J Neurol, 1992,239 ( 1 ): S28 -S34.
  • 4Mentenopolous G, Katsarou Z, Bostantjopoulou S, et al. Piribedil therapy in Parkinson's disease [J]. Clin Neuropharm, 1989,12: 23 - 28.
  • 5Ziegler M, Castro CA, Del SS, et al. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease:A 6 - month, randomized, placebo - controlled study [J]. Mov Disord,2003,18:418 - 425.
  • 6Joehn GN,Juhr PH, Stephen TG. Parkinson's disease( 100 Maxims)[J]. London: Edwanl Arndd, 1992:74 - 75.
  • 7王新德.金森病及帕金森综合征的诊断标准和鉴别诊断[J].中华神经精神科杂志,1985,18(4):255-255.
  • 8Perachon S, Schwartz JC, Sokoloff P. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3receptors [J]. Eur J Pharmacol, 1999,366 (2 - 3): 293 - 300.
  • 9Lebrun F C, Borg M. Choosing the right dopamine agonist for patients with Parkinson's disease [J]. Curr Med Res Opin. 2002, 18(4) :209 - 14.
  • 10Uslu B, Ozkan SA. Electroanalytical characteristics of piribedil and its differential pulse and square wave voltammetric determination in pharmaceuticals and human serum [J]. J Pharm Biomed Anal,2003,31(3):481-489.

共引文献13

同被引文献16

引证文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部